Neuren Pharmaceuticals Ltd (NEU.AU) saw its stock price soar 5.12% during intraday trading on Wednesday, following a significant commercial update for its key product.

The sharp price increase is directly linked to the company's announcement that Daybue Stix, its treatment for Rett Syndrome, is now broadly available in the United States. This expanded market access is a major commercial milestone, potentially increasing the product's reach to patients and driving future revenue growth for the pharmaceutical company.